A Trial Evaluating Safety of Chronic Therapy With Certolizumab Pegol in Crohn's Disease
Crohn's Disease
About this trial
This is an interventional treatment trial for Crohn's Disease focused on measuring certolizunab pegol, long term safety follow-up, Chrohn's disease, infliximab failures patients, Greek population
Eligibility Criteria
Inclusion Criteria: Crohn's disease diagnosis Patients having completed the treatment period of study C87055 (previously treated with infliximab) and benefited from the study treatment, as per investigatior's discretion. Exclusion Criteria: Subject withdrawn prematurely from C87055 study. Subject who received treatment other than certolizumab pegol and other than medications permitted in C87055 study. Female patients of childbearing age who are NOT practicing (in the Investigator's opinion) effective birth control. All female patients must test negative on a serum pregnancy test before study entry and negative on urine testing immediately before every certolizumab pegol administration.